Amgen’s comments Thursday that it’s “very encouraged” by interim Phase 2 data for its obesity drug have quickly sparked immense investor interest in what could be a potential contender with Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound.
The injectable drug MariTide, designed to be given monthly, could be a more attractive option than Wegovy and Zepbound, which are both dosed weekly. While the Phase 2 trial is still ongoing, Amgen is already planning to run a broad Phase 3 program and scale up manufacturing “with both clinical and commercial supply in mind,” Chief Executive Bob Bradway said on an earnings call.
Even though executives shared no data from the interim analysis of its injectable drug, excitement around the molecule has already sent Amgen’s stock up 12% Friday.
Click this link for the original source of this article.
Author: Elaine Chen
This content is courtesy of, and owned and copyrighted by, https://www.statnews.com and its author. This content is made available by use of the public RSS feed offered by the host site and is used for educational purposes only. If you are the author or represent the host site and would like this content removed now and in the future, please contact USSANews.com using the email address in the Contact page found in the website menu.